Spinal Muscular Atrophy (SMA)MyokinesisNCT07321977
Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers
A study testing Gait analysis via video capture in people with Spinal Muscular Atrophy (SMA) and Charcot-Marie-Tooth, run by Institut de Myologie, France at 1 site in France.
Trial summary
In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth, Muscular Dystrophy
- What is being tested?
- Gait analysis via video capture
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- 3 Mar 2026to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- All volunteers
- Individuals under guardianship, curatorship, or legal protection
- Pregnant or breastfeeding women
- Non-ambulatory individuals
- Individuals with epilepsy
- Skin conditions preventing the placement of VICON motion sensors
Show all 17Show fewer
- Asymptomatic volunteers
- Unstable respiratory or cardiac problems
- Neurological, musculoskeletal, or psychiatric problems
- Volunteers with a neuromuscular disease
- Recent trauma or serious falls (≤ 6 months)
- Individuals who have fallen more than twice in the past year and at least once in the past three months
- Use of assistive devices such as rigid knee braces or walkers
- Unstable cardiomyopathy
- Individuals awaiting diagnosis
- Inability to comply with the protocol requirements
- Medical or social conditions that could interfere with the study, as determined by the coordinating investigator or co-investigators.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre d'Exploration et d'Évaluation Neuromusculaire
Paris
Romain FEIGEAN, PhD, +33 01 42 16 58 80, r.feigean@institut-myologie.org
About this study
In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Current gait tests only consider the time factor and not the evolution of the patient's biomechanics, which may prove insufficient for patients whose symptoms generally progress slowly. Quantifying gait parameters in neuromuscular patients therefore appears necessary. This is why we propose to study markerless gait analysis in this population, which would allow for simple and effective monitoring of kinematic parameters without resorting to complex equipment incompatible with routine clinical practice.
- Conditions
- Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth, Muscular Dystrophy, Myotonic Dystrophy
- Being tested
- Gait analysis via video capture
- Keywords
- gait analysis, neuromuscular, disease, markerless
- Medical subject headings
- Muscular Atrophy, Spinal, Charcot-Marie-Tooth Disease, Muscular Dystrophies, Myotonic Dystrophy, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gait analysis via video captureOther
Using motion analysis software integrated into a smartphone
| Study group | Role | What they receive |
|---|---|---|
| Volunteers with Neuromuscular disease or asymptomatic | Other | All participants have the same intervention. The intervention is to walk with shoes in a gait analysis room with VICON markers on the body. At the same time, the participant will be film by two smartphones to compare the kinematics and the spatio-temporal parameters between a marker-based and a markerless gait analysis. Receives: Other: Gait analysis via video capture |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vicon vs Myokinesis system correlation coefficient
Correlation coefficient between measurements from the two systems in both groups, for spatiotemporal parameters and joint range of motion in the sagittal plane at the hip, knee, and ankle
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2026
- Study start3 Mar 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Spinal Muscular Atrophy (SMA)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut de Myologie, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07321977
- Sponsor's protocol ID
- Myokinesis
- Acronym
- Myokinesis
- Status last verified
- Nov 2026
- First submitted
- 15 Dec 2025
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers
- ClinicalTrials.gov ID
- NCT07321977
- Acronym / sponsor ID
- Myokinesis / Myokinesis
- Conditions
- Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth, Muscular Dystrophy, Myotonic Dystrophy
- Keywords
- gait analysis, neuromuscular, disease, markerless
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Institut de Myologie, FranceUniversity, hospital or other
- Study start
- 3 Mar 2026 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 7 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Current gait tests only consider the time factor and not the evolution of the patient's biomechanics, which may prove insufficient for patients whose symptoms generally progress slowly. Quantifying gait parameters in neuromuscular patients therefore appears necessary. This is why we propose to study markerless gait analysis in this population, which would allow for simple and effective monitoring of kinematic parameters without resorting to complex equipment incompatible with routine clinical practice.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Volunteers with Neuromuscular disease or asymptomatic | Other | Other: Gait analysis via video captureAll participants have the same intervention. The intervention is to walk with shoes in a gait analysis room with VICON markers on the body. At the same time, the participant will be film by two smartphones to compare the kinematics and the spatio-temporal parameters between a marker-based and a markerless gait analysis. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (17 listed)
- All volunteers
- Asymptomatic volunteers
- Volunteers with a neuromuscular disease
- Inability to comply with the protocol requirements
- Medical or social conditions that could interfere with the study, as determined by the coordinating investigator or co-investigators.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gait analysis via video captureUsing motion analysis software integrated into a smartphone | Other | Volunteers with Neuromuscular disease or asymptomatic |
Primary outcome
Vicon vs Myokinesis system correlation coefficient
Time frame: Day 1
Correlation coefficient between measurements from the two systems in both groups, for spatiotemporal parameters and joint range of motion in the sagittal plane at the hip, knee, and ankle
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
Related trials for Spinal Muscular Atrophy (SMA)
Active, not recruitingPhase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Muscular Atrophy, Spinal
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
RecruitingObservational study
A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)
Spinal Muscle Atrophy
RecruitingPhase 3
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Metastatic Castration Resistant Prostate Cancer
RecruitingObservational study
An International Federated Model for Wearable-derived Remote Longitudinal Motor Monitoring in Young Children With Spinal Muscular Atrophy Compared With Healthy Controls: Active-NBS Study (UK)
Spinal Muscular Atrophy (SMA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Gait analysis via video capture in people with Spinal Muscular Atrophy (SMA) and Charcot-Marie-Tooth, run by Institut de Myologie, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pauline SANTMARTY, MsC (+33 01 42 16 58 79, p.santmarty@institut-myologie.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vicon vs Myokinesis system correlation coefficient (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.